Feedback / Questions
SIL-204 subcutaneous - Silexion Therapeutics
https://www.globenewswire.com/news-release/2025/12/02/3197820/0/en/Silexion-Therapeutics-Receives-Positive-Feedback-from-German-Health-Authority-on-Design-of-Phase-2-3-Clinical-Trial-in-Pancreatic-Cancer.html
Dec 2, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next